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(57) ABSTRACT 
The novel compound of the disclosure is 4-chloro-4-( 4-
ethoxy-pheny 1)-2-( fiuoren-9-y lidene-hydrazono )-but-3-
enoic acid methyl ester (3F-19), and it alone or in combi-
nation with 4-( 4-Ethoxy-phenyl)-2-(N'-fiuoren-9-ylidene-
hydrazino)-2-hydroxy-4-oxo-butyric acid methyl ester (OF-
13), appears useful in humans as therapeutic means for the 
eradication of tumors from the human's colon. 
4 Claims, 1 Drawing Sheet 
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TREATMENT OF COLON CANCER 
FIELD OF THE INVENTION 
This is a Divisional of application Ser. No. 10/164,879 
filed Jun. 7, 2002, and this invention relates to the use of 5 
novel compounds alone or in combination or treatment of 
human colon cancer and claims the benefit of priority of U.S. 
Provisional Application Ser. No. 60/296,823 filed Jun. 8, 
2001. 
10 
BACKGROUND OF THE INVENTION 
Cancer is a global killer of humans with breast cancer and 
colon cancer among the leaders with many other types 
killing modest amounts of humans yearly. Breast cancer is 15 
the primary killer of women. Colon cancer is the third 
greatest killer of people in the United States. 
2 
which are said to inhibit tumor metastasis (column 7, line 
56 and column 8, line 4); 
Frechette (U.S. Pat. No. 5,696,117), Frechette (U.S. Pat. No. 
5,854,242) and Frechette (U.S. Pat. No. 5,707,990) 
describe 148 benzoxazine and pyrido-oxazine heterocy-
clic as anti-bacterial compounds; 
Omedi-Sale (U.S. Pat. No. 3,862,954) shows tri-azole com-
pounds for CNS use; 
Hawkins (U.S. Pat. No. 5,274,002) describes many analogs 
of phenyl ethers of a substituted phenyl of the formula 
structure at column 1, lines 49-60 with 37 examples of 
specific compounds which compounds may be useful for 
tumor inhibition (column 22, line 64); and, 
Boyd, et al (U.S. Pat. No. 6,080,790) also describes many 
tri-substituted phenyl derivatives according to the formula 
of the Abstract with 15 examples of specific compounds 
which may be useful for malignant skin diseases (column 
5, line 46). 
It appears from a review of the foregoing patents that 
Colon cancer although having an excellent cure rate is a 
very common cancer second only to lung cancer in the 
United States. 129,400 new cases of colorectal cancer were 
estimated for 1999 with 56,600 deaths therefrom. The stron-
gest risk factor for colon cancer is age. The incidence rates 
rise from 10 per 100,000 at age 40-45 to 300 per 100,000 at 
age 75-80. The cumulative life time risk for the disease is 1 
in 20. Men are more likely to develop colon cancer than 
women. Black Americans are more likely than white Ameri-
cans to be diagnosed with colorectal cancer. Smokers, 
drinkers, sedentary, and obese persons are more likely to 
develop colon cancer. 
20 neither the 2-hydrazino-3-oxo-butenoic acid nor the 
2-hydroxy-4-oxobutyric acid derivatives of interest are dis-
closed and thus there is no report of their activity against 
human colon cancer. 
Consequently, there is a need for an anti-cancer drug for 
25 humans that mitigate the above mentioned disadvantages of 
current drug therapy and effectiveness against the identified 
human colon cancer. 
The U.S. patent literature has many disclosures of oxo- 30 
butenoic ( crotonic) compounds: 
Pamukci (U.S. Pat. No. 6,232,312) describes crotonic acid 
derivatives (column 22, lines 43-58) for the treatment of 
colonic polyps; 
Jones et al (U.S. Pat. No. 6,121,450) discloses crotonic acid 35 
derivatives (column 8, line 34; column 78, line 24 and at 
example 34 as steroid modifiers in treating breast cancer 
(column 1, lines 55-58); 
Kalden, et al (U.S. Pat. No. 5,334,612) discloses compounds 
said to be useful for treating AIDS including derivatives 40 
of carboxylic acid (column 9, line 31) and pyrrolidine 
(column 7, line 24); 
SUMMARY OF THE INVENTION 
The first objective of the present invention is to provide a 
novel drug effective for treatment of human colon cancer. 
Another object of this invention is to provide a novel 
2-hydrazino-3-oxo-butenoic acid derivative. 
A preferred embodiment of the invention encompasses the 
specific compounds: 4-Chloro-4-( 4-ethoxy-phenyl)-2-
(fluoren-9-ylidene-hydrazono)-but-3-enoic acid methyl 
ester (3F-19), and the use of it and/or 4-(4-Ethoxy-phenyl)-
2-(N' -fl uoren -9-y lidene-hydrazino )-2-h ydroxy-4-oxo-
butyric acid methyl ester (OF-13) in humans as therapeutic 
means for the eradication of tumors from the human's colon. 
Brown (U.S. Pat. No. 6,066,670) describes an anti-viral 
admixture containing crotonic acid for treating tumors 
(see Abstract); 
Further objects and advantages of this invention will be 
apparent from the following detailed description of presently 
45 preferred embodiments, which are illustrated structurally in 
the accompanying drawings. Harwell, et al (U.S. Pat. No. 5,580,896) discloses many 
4-oxo-2-butenoic acid derivatives (column 13, lines 
21-59; also in columns 15+, examples 25, 26, 32, 34, 40, 
43-46, 77-79, 97, 99, 103, 106,), which are useful for 
inhibiting colorectal cancer, i.e., colon cancer (Abstract); 50 
Giordani, et al (U.S. Pat. No. 5,580,890) discloses 4-oxo-
2-butenoic acid derivatives said to be useful for treatment 
of AIDS (column 1, line 8 and column 2, line 61; and, 
Yonemeto, et al (U.S. Pat. No. 6,083,985) recites a number 
of anti-tumor or anti-AIDS agents that include butenoic 55 
acid derivatives. 
The U.S. patent literature has many disclosures of 
butanoic acid derivatives including: 
Nicolai, et al (U.S. Pat. No. 6,180,651) discloses many 
anti-inflammatory and analgesic compounds, including 60 
adenocarcinoma (column 1, line 55), which includes 
heterocyclic alcohol-esters (column 11, lines 1-16) and 
butanoic acid derivatives (many Examples including 47 
through 162); 
Girard, et al (U.S. Pat. No. 5,308,852) discloses many 65 
compounds including butanoic acid derivatives (see 
Methods B and C of schemes II and III) which compounds 
BRIEF DESCRIPTION OF THE FIGURES 
FIG. 1 illustrates structurally a chemical compound des-
ignated as 3F-19. 
FIG. 2 illustrates structurally a chemical compound des-
ignated as OF-13. 
DESCRIPTION OF THE PREFERRED 
EMBODIMENTS 
Before explaining the disclosed embodiments of the 
present invention in detail, it is to be understood that the 
invention is not limited in its application to the details of the 
particular arrangement shown since the invention is capable 
of other embodiments. Also, the terminology used herein is 
for the purpose of description and not of limitation. 
As earlier recited this application has been filed in order 
to both disclose the novel 2-hydrazino-3-oxo-butenoic acid 
derivative structurally shown in FIG. 1 as well as the use of 
US 6,858,748 Bl 
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the structure in FIGS. 1 and/or 2 for biological activity 
useful for the treatment of human colon cancer. More 
specifically this application discloses the anti-tumor com-
pounds: 4-Chloro-4-( 4-ethoxy-pheny 1)-2-( fluoren-9-
ylidene-hydrazono )-but-3-enoic acid methyl ester (3F-19); 5 
and, 4-( 4-Ethoxy-phenyl) 2 -(N'-fluoren-9-ylidene-
hydrazino)-2-hydroxy-4-oxo-butyric acid methyl ester (OF-
13). 
4 
Preparation of OF-13 
EXAMPLE 2 
The preparation of 4( 4-Ethoxyphenyl)-2-(N'-fluoren-9-
ylidene-hydrazino )-2-hydroxy-4-oxobutyric acid methyl 
ester (OF-13). A solution of 5.0 g (0.02 moles) of methyl To facilitate a fill understanding of the invention: 
the compound designated as 3F-19 is 4-Chloro-4-( 4-ethoxy-
phenyl)-2-fluoren-9-ylidene-hydrazono )but-3-enoic acid 
methyl ester; and 
the compound designated as OF-13 is 4-(4-Ethoxy-
pheny 1)-2-N'-fluoren-9-ylidene-hydrazino )-2-hydroxy-
4-oxo-butyric acid methyl ester. 
10 4-p-ethoxyphenyl-2-hydroxy-4-oxo-2-butenoate (1) and 
3.88 g (0.02 moles) of fluorene-9-ylidene-hydrazine (2) in 
80 mL of absolute benzene and absolute toluene (1:1) was 
refluxed for 1 hr 30 min with a Dean-Stark trap (the end of 
the reaction was determined by TLC), cooled and the 
15 
These compounds have very high activity against colon 
cancer and a very low toxicity as a (LD50) in animals. The 
percent activity and animal toxicity for each compound is as 
follows: 
3F-19 (100% against human colon cancer and LD50>200 20 
mg/kg); and, 
OF-13 (100% against human colon cancer and LD50>1500 
mg/kg). 
Preparation of (3F-19) 
EXAMPLE 1 
25 
The preparation of 4-Chloro-4( 4-ethoxy-phenyl)-2-
(fluoren-9-ylidene-hydrazono )-but-3-enoic acid methyl 
ester (3F-19) To the solution of 10 g (0.0026 moles) of 30 
4-( 4-Ethoxy-phenyl)-2-(N'-fluoren-9-lidene-hydrazino )-4-
oxo-but-2-enoic acid methyl ester (1) (synthesis was previ-
ously published by Konyukhova, N. A Krasnykh, 0. P.; 
Aliev, Z. G.; Maslivets, A N. Chemistry of Heterocyclic 
Compounds (New York, N.Y., United States)(Translation of 35 
Khimiya Geterotsiklicheskikh Soedinenii) (2001), 37(6), 
779-780) in 5 mL of anhydrous benzene 0.3935 g (0.0031 
moles) oxalyl chloride was added. The reaction mixture was 
refluxed for 1 hour 40 min, cooled, the precipitate was 
filtered and recrystallized from absolute benzene to give 
0.62 g (54%) of yellow crystals, m.p. 163-163 (decamp). 
precipitate was filtered and recrystallized from benzene-
diethyl ether-hexane mixture (1:3:2) to give 2.65 g (53% 
yield) of colorless crystals with mp 114-116° C. 
Solubility: highly soluble in DMSO, DMFA, 
dichloroethane, acetonitrile, insoluble in hexane. The com-
pound is not stable in solutions and decomposes quickly 
when the solution is heated or stored for a long time with the 
formation of OF-12. 
~COOCH3+ 
C2HsO~ ~, __ 
0 OH 
2 
C2H5o--O--co-cH2-IT-coocH3 
/N 
N 
ocn cPo 
(COCl)2i 
HsC20--0--1=cH-IT-coocH3 
Cl /N 
ciD 
3F-19 
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-continued 
OH ~COOCH3 
C2HsO~ , __ _ 
0 NH 
~ 
U-----V 
OF-12 
It is seen from the above that (OF-13) is an intermediate 
product during the synthesis of (OF-12). 
Cytotoxicity Assay. 
The antitumor activity against human colon cancer cells 
of the novel compounds (as earlier reported) was realized by 
the following procedure which determines the inhibitory 
effect of test samples on the growth of human colon cancer 
cells (ATCC CCL220). The CCL220 cells are grown in 
RPMI 1640 media+10% Fetal bovine serum+l % Antibiotic/ 
Antimycotic for approximately 48 hours at 37° C./5% C02 
in the presence of the test compound. 
5 
10 
6 
Matrix-solvent that the samples are prepared/diluted in 
Assay samples of similar origin and matrix (e.g., methanol 
extraction, methylene chloride extraction, water soluble 
samples, etc.) together on the same plate in order to 
reduce the number of steps performed per plate. 
Blank values will be determined for each sample to account 
for any color contribution due to the sample itself. These 
blank wells must contain the same amount of sample plus 
CCL220 media (no cells). After completion of MTS/PMS 
reaction blank values will be subtracted from the test 
value to obtain a net absorbance that will be used to 
calculate cell density. 
All results are based upon a comparison to the Negative 
Control value of the plate. The Negative Control must 
15 contain the same amount of matrix (e.g., solvent) to offset 
any destructive effect the matrix may have on the growth of 
the CCL220 cells (allows for baseline values to be set). 
For most samples, a CCL220 cell growth (initial density 
of 120,000 to 160,000 cells/ml) of approximately 48 hours 
20 followed by and incubation of 2 hours with the MTS/PMS 
Reagent is optimal. 
In order to establish the accuracy of this assay a Positive 
Control consisting of 50 µM Methotrexate should not 
decrease the net absorbance to less than 90% of the Negative 
25 Control (CCL220 cells are somewhat resistant to 
methotrexate) is utilized. 
Animal Toxcity Bioassay 
Acute toxicity was studied on white mice of both sexes 
with weight ranging between 18-26 grams under intraperi-
30 toneal injection of 2% solution of tested compound in starch 
(the compound was dissolved in starch slime and injected) 
on the basis of 0.1 ml of solution per 10 g of the animal 
weight Each dose was tested on the group of 6 animals that 
were observed during 14 days period. (This method was 
35 approved by the Pharmacology committee of Russian Min-
istry of Health and has been widely used since 1968.) 
Averaged lethal dose (LD50) of the compound was com-
puted using results of experiments on 5-7 groups of animals 
using method of Litchfield and Wilkinson. (Belenkii M. L. 
40 "Elements of quantative determination of the pharmacologi-
cal effect," Leningrad, 1963, 71 pages). 
Use of the Invention for Treatment of Human Colon Cancer 
Growth/Non-Growth of the cells (e.g., cell density) is 
determined using Promega's MTS/PMS assay system. MTS 
( 3 - ( 4 , 5 - d i m e t h y 1 t h i a z o 1 - 2 - y 1) - 5 - ( 3 - 45 
Due to their low toxicity data, the compounds described 
as useful in this invention can be used effectively in a 
pharmaceutical composition comprising a non-toxic effec-
tive amount of the referenced compound or mixture thereof 
carboxymethoxypheny 1)-2-( 4-sulfopheny l)-2H-tetrazolium, 
inner salt) is an aqueous compound that is reduced to soluble 
formazan by the presence of NADH formed by dehydroge-
nases present within the CCL220 cells. The absorbance of 
the formazan can be measured at 490 nm and is directly 50 
proportional to the number of living cells present in the 
culture. PMS (Phenazine Methosulfate) is added an electron 
coupling reagent and greatly increases the rate of reduction. 
and/or in a tautomeric form thereof or a pharmaceutically 
acceptable salt thereof or pharmaceutically acceptable sol-
vate thereof, and a pharmaceutically acceptable carrier 
thereof. 
For administration to man in the curative or prophylactic 
treatment of human colon cancer in vitro dosages of 
compound(s) and admixtures thereof the invention will 
generally be in the range of from 5 to 500 mg daily for an To facilitate a full understanding of the procedure the 
following definitions are offered: 
Test wells-wells containing test sample and Diluted 
CCL220 cells 
Test values-absorbance of test wells 
Blank wells-wells containing test sample and CCL220 
media (C220-01S); used to obtain background absorbance 
due to test sample 
Blank values-absorbance of blank wells 
Negative Control-maximal cell growth; results of test 
samples will be expressed as a percent of the Negative 
Control 
Positive Control-known inhibitor of CCL220 cells; used to 
validate assay system 
55 average adult patient (70 kg). Thus for a typical adult 
patient, individual tablets or capsules contain from 2-500 
mg of active compound, in a suitable pharmaceutically 
acceptable vehicle or carrier, for administration in single or 
multiple doses, once or several times per day. Dosages for 
60 intraveneous, buccal or sublingual administration will typi-
cally be within the range of from 5-1000 mg per single dose 
as required. The physician will determine the actual dosing 
regimen which will be most suitable for an individual patient 
by periodic colonoscope and/or anal blood examination to 
65 evaluate the tumor inhibitory effect of the compound(s) 
administered and it will vary with the age, weight and 
response of the particular patient. 
US 6,858,748 Bl 
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The maximum human non-toxic one time administration 
dose for the compound(s) of the invention appears to 
100--750 mg. 
8 
cancer and also but not as well documented Stage III Rectal 
Cancer. The benefit for Stage II is still unclear. The increase 
in 5-year survival is in the range from 50% up to 65% for 
Stage III Colon Cancer. The drugs being used are 5-FU For human use, the compounds of the invention can be 
administered alone or jointly, but will generally be admin-
istered in admixture with a pharmaceutical carrier selected 
with regard to the intended route of administration and 
standard pharmaceutical practice. For example, they may be 
administered orally, buccally or sublingually, in the form of 
tablets containing excipients such as starch or lactose, or in 
capasules or ovules either alone or in admixture with 
excipients, or in the form of elixirs or suspensions contain-
ing flavouring or colouring agents. The compounds may also 
5 (fiuorouracil)+Leucovorin or 5-FU+Levamisol. It should be 
mentioned that 5-FU drug has been already used for more 
than 30 years. 
Toxicity of 5-FU drug in mice is IPN-Mice LD50 230 mg 
kg-1 . It should be compared with IPN-Mice 1500 mg kg-1 
10 toxicity of the claimed drug. Consequently the claimed 
drugs provide basis for the development of new drugs with 
less side effects and lower toxicity. 
be injected parenterally, for example intraveneously, 
intramuscularly, subcutaneously or intracoronarily. For 15 
parenteral administration, they are best used in the form of 
a sterile aqueous solution which may contain other 
substances, for example enough salts or glucose to make the 
solution isotonic with blood. 
The invention thus provides a method for the treatment of 
colon cancer in a human mammal which comprises admin-
istering an effective, non-toxic, amount of a compound 
according to the invention or a tautomeric form thereof 
and/or a pharmaceutically acceptable salt thereof and/or a 
pharmaceutically acceptable solvate thereof, to a: colon 25 
cancer invaded human mammal in need thereof. 
While the invention has been described, disclosed, illus-
trated and shown in various terms of certain embodiments or 
modifications which it has presumed in practice, the scope 
of the invention is not intended to be, nor should it be 
deemed to be, limited thereby and such other modifications 
or embodiments as may be suggested by the teachings herein 
are particularly reserved especially as they fall within the 
20 breadth and scope of the claims here appended. 
We claim: 
1. A mixture suitable for administration to a human being 
comprising 4-Chloro-4-( 4-ethoxy-pheny 1)-2-(fiuoren-9-
ylidene-hydrazono )-but-3-enoic acid methyl ester and 4-( 4-
Ethoxy-pheny 1)-2-(N' -fiuoren -9-y lidene-h ydrazino )-2-
hydroxy-4-oxo-butyric acid methyl ester having the 
property of anti-tumor activity against colorectal cancer. ADVANTAGES OF THE INVENTION 2. A method of treating a human having colon cancer 
comprising the step of: administering an effective amount of 
30 4-Chloro-4-( 4-ethoxy-pheny 1)-2-( fiuoren-9-y lidene-
hydrazono )-but-3-enoic acid methyl ester to said human. 
3. A method of treating a human having colon cancer 
comprising the step of: administering an effective amount of 
4-( 4-Ethoxy-pheny 1)-2-(N'-fiuoren-9-ylidene-hydrazino )-2-
35 hydroxy-4-oxo-butyric acid methyl ester to said human. 
Surgery is the primary treatment for colon cancer and the 
only treatment that can cure the patient. Adjuvant Chemo-
therapy means that you treat with chemotherapy after the 
operation that has removed all visible tumor tissue to kill 
single cancer cells or micro metastatic tumor deposits that 
may have spread from the primary tumor before or at the 
time of surgery through blood or lymph vessels to diminish 
the risk of clinically evident distant metastases. The effect of 
adjuvant chemotherapy after colon cancer has been debated 
for many years and many studies have been made, some not 
showing any benefit, but some showing a benefit. There is an 
40 increasing number of recent studies and meta analyses 
showing a positive effect on Stage III (node positive) colon 
4. The method according to claim 3 further comprising 
administering an effective amount of 4-(4-ethoxy-phenyl)-
2-(fiuoren-9-ylidene-hydrazono )-but-3-enoic acid methyl 
ester. 
* * * * * 
